Author

J. Smith

Observed name: Smith, J.

Institution: UCB Pharma (United Kingdom)

Observed institutions: University of Wisconsin–Madison, UCB Pharma (United Kingdom)

OpenAlex ID: A5055089985

Pos0939 Bimekizumab in Patients With Active Non-radiographic Axial Spondyloarthritis: 24-week Efficacy & Safety From Be Mobile 1, a Phase 3, Multicentre, Randomised, Placebo‑controlled Study

2022 · A. Deodhar, D. Van der Heijde, et al. · Annals of the Rheumatic Diseases · 5

Ab0938 Safety Profile of Bimekizumab at Week 16 in Patients With Axial Spondyloarthritis and Psoriatic Arthritis: Results From Four Placebo-controlled Phase 3 Studies

2023 · D. Poddubnyy, L.S. Gensler, et al. · Annals of the Rheumatic Diseases · 1

Pos0173 Data-driven Mri Definitions for Active and Structural Sacroiliac Joint Lesions in Juvenile Spondyloarthritis Typical of Axial Disease

2022 · P.F. Weiss, T.G. Brandon, et al. · Annals of the Rheumatic Diseases · 1

Works count: 4

Citation count: 7

H-index: 1

I10-index: